Lin Z, Yu S, Yang Y, et al (2024) The double-edged effects of substance P in the pathology of Alzheimers disease
Because many peptides are not FDA-approved, the full long-term safety profile is not established, which is why medical supervision and dose individualization are important
Hyperprolinemia type I caused by homozygous p.T466M mutation in PRODH
Optimizing topical therapies for treating psoriasis: 36
Anyone considering these peptides should exercise caution, consult qualified healthcare professionals, and prioritize high quality sources
With additional clinical trials under way, and the development of a fixed-dose combination product of GLP-1 RA and basal insulin, the use of GLP-1 RA as an alternative to prandial insulin seems likely to increase with time